Pretomanid market price, medical insurance reimbursement policy and drug purchase reference prices in various regions

Pretomanid (Pretomanid) is a drug used to treat multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) anti-tuberculosis drugs, usually used in combination with bedaquiline (Bedaquiline) and rifampicin (Linezolid). The drug exerts a powerful antibacterial effect by inhibiting the cell wall synthesis and energy metabolism of Mycobacterium tuberculosis, providing a new treatment option for patients with drug-resistant tuberculosis.

In the domestic market, Putomani has not yet been officially launched, the specific price information is not clear, and the medical insurance reimbursement policy is not clear either. Patients are temporarily unable to purchase the drug through formal channels in China, so domestic use mainly relies on clinical trials or hospital supply after it is officially launched in the future. As the drug is approved in China and included in medical insurance, it is expected to provide patients with drug-resistant tuberculosis with more convenient and economical medication options.

Putomani in overseas markets is relatively expensive. The specifications of the original drug are 200mg*26 tablets. Each box sells for about more than 600 US dollars. The high price mainly reflects the cost of research and development and the highly targeted nature of the drug. For patients with limited financial resources, this price may constitute a greater burden and limit the broad accessibility of the drug.

In order to reduce the cost of medication, generic versions of putomanid have also appeared overseas. For example, the specification of 200mg*30 tablets produced by a Lao pharmaceutical factory is priced at about more than 2,000 yuan per box (the price may fluctuate due to exchange rates). Although generic drugs are more affordable, patients still need to obtain them through formal channels and use them in combination under the guidance of a doctor to ensure efficacy and safety. In the future, the launch of domestic drugs and medical insurance coverage may further improve patient accessibility and economic burden.

Reference materials:https://www.drugs.com/